



US007594934B2

(12) **United States Patent**
Stone

(10) **Patent No.:** **US 7,594,934 B2**
(45) **Date of Patent:** **Sep. 29, 2009**

(54) **GALACTOSIDASE-TREATED PROSTHETIC DEVICES**

See application file for complete search history.

(75) Inventor: **Kevin R. Stone**, Mill Valley, CA (US)

(56) **References Cited**

(73) Assignee: **Crosscart, Inc.**, San Francisco, CA (US)

U.S. PATENT DOCUMENTS

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 507 days.

4,880,429 A *	11/1989	Stone	623/14.12
5,108,438 A *	4/1992	Stone	623/17.16
5,116,374 A *	5/1992	Stone	435/325
5,984,858 A *	11/1999	Stone	600/20
6,046,379 A *	4/2000	Stone et al.	623/14.12
6,231,608 B1 *	5/2001	Stone	623/16.11

(21) Appl. No.: **10/517,863**

FOREIGN PATENT DOCUMENTS

(22) PCT Filed: **Jun. 4, 2003**

WO WO 00/47132 8/2000

(86) PCT No.: **PCT/US03/17444**

* cited by examiner

§ 371 (c)(1),
(2), (4) Date: **Jun. 6, 2005**

Primary Examiner—Suzette J Gherbi
(74) *Attorney, Agent, or Firm*—John M. Garvey; Matthew L. Fenselau; Foley & Lardner LLP

(87) PCT Pub. No.: **WO03/105737**

PCT Pub. Date: **Dec. 24, 2003**

(57) **ABSTRACT**

(65) **Prior Publication Data**

US 2005/0221703 A1 Oct. 6, 2005

Matrix material for a substantially immunologically-compatible meniscal augmentation device of biocompatible and partially bioresorbable fibers is prepared by treatment with oc-galactosidase to eliminate oc-Gal epitopes. Upon implantation into a segmental defect of a meniscus, the composite of the meniscal augmentation device and the meniscus establishes a scaffold adapted for ingrowth of meniscal fibrochondrocytes.

(51) **Int. Cl.**
A61F 2/36 (2006.01)
A61F 2/38 (2006.01)

(52) **U.S. Cl.** 623/23.72; 623/11.11; 623/23.76

(58) **Field of Classification Search** 623/13.17, 623/16.11, 23.61–23.64, 23.72–23.76; 424/422, 424/423

7 Claims, 7 Drawing Sheets

